VTYX - Ventyx stock craters on disappointing Phase 2 results for psoriasis drug candidate
2023-11-06 17:03:58 ET
More on Ventyx Biosciences
- Ventyx: Promising, But Data Will Need To Justify Optimistic Valuation
- Ventyx Biosciences, Inc. (VTYX) Q2 2023 Earnings Call Transcript
- Ventyx stock plunges following Phase 2 results for ulcerative colitis drug
- Seeking Alpha’s Quant Rating on Ventyx Biosciences
- Historical earnings data for Ventyx Biosciences
For further details see:
Ventyx stock craters on disappointing Phase 2 results for psoriasis drug candidate